Literature DB >> 32450787

Liver injury in COVID-19: The current evidence.

Saleh A Alqahtani1,2, Jörn M Schattenberg3.   

Abstract

Patients with novel coronavirus disease 2019 (COVID-19) experience various degrees of liver function abnormalities. Liver injury requires extensive work-up and continuous surveillance and can be multifactorial and heterogeneous in nature. In the context of COVID-19, clinicians will have to determine whether liver injury is related to an underlying liver disease, drugs used for the treatment of COVID-19, direct effect of the virus, or a complicated disease course. Recent studies proposed several theories on potential mechanisms of liver injury in these patients. This review summarizes current evidence related to hepatobiliary complications in COVID-19, provides an overview of the available case series and critically elucidates the proposed mechanisms and provides recommendations for clinicians.

Entities:  

Keywords:  COVID-19; SARS-CoV2; cholangiocytes; cytokine storm; liver function test; liver injury; lymphopenia

Mesh:

Substances:

Year:  2020        PMID: 32450787     DOI: 10.1177/2050640620924157

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  61 in total

1.  Gastroenterological features of COVID-19 and the role of the United European Gastroenterology Journal.

Authors:  Fernando Magro; Joost Ph Drenth
Journal:  United European Gastroenterol J       Date:  2020-06       Impact factor: 4.623

2.  Extensive Study on Hematological, Immunological, Inflammatory Markers, and Biochemical Profile to Identify the Risk Factors in COVID-19 Patients.

Authors:  Eman T Ali; Azza Sajid Jabbar; Hadeel S Al Ali; Saad Shaheen Hamadi; Majid S Jabir; Salim Albukhaty
Journal:  Int J Inflam       Date:  2022-04-21

3.  Postmortem pathological changes in extrapulmonary organs in SARS-CoV-2 rt-PCR-positive cases: a single-center experience.

Authors:  Aytul Bugra; Taner Das; Murat Nihat Arslan; Nihan Ziyade; Yalcın Buyuk
Journal:  Ir J Med Sci       Date:  2021-05-07       Impact factor: 1.568

4.  Cautions on the laboratory indicators of COVID-19 patients on and during admission.

Authors:  Haiting Liu; Xueling Shang; Sai Chen; Tie Li; Junhua Zhang
Journal:  J Clin Lab Anal       Date:  2021-05-05       Impact factor: 2.352

5.  Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study.

Authors:  Coskun Ozer Demirtas; Caglayan Keklikkiran; Ilkay Ergenc; Buket Erturk Sengel; Gunes Eskidemir; Ismail Cinel; Zekaver Odabasi; Volkan Korten; Yusuf Yilmaz
Journal:  Int J Clin Pract       Date:  2021-05-29       Impact factor: 3.149

Review 6.  The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.

Authors:  Ren-Jun Hsu; Wei-Chieh Yu; Guan-Ru Peng; Chih-Hung Ye; SuiYun Hu; Patrick Chun Theng Chong; Kah Yi Yap; Jamie Yu Chieh Lee; Wei-Chen Lin; Shu-Han Yu
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 7.  Neuropilin-1: A feasible link between liver pathologies and COVID-19.

Authors:  Aitor Benedicto; Iñigo García-Kamiruaga; Beatriz Arteta
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

Review 8.  Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know?

Authors:  Anna Licata; Maria Giovanna Minissale; Marco Distefano; Giuseppe Montalto
Journal:  GastroHep       Date:  2021-05-03

Review 9.  Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis.

Authors:  Donovan A McGrowder; Fabian Miller; Melisa Anderson Cross; Lennox Anderson-Jackson; Sophia Bryan; Lowell Dilworth
Journal:  Diseases       Date:  2021-07-01

10.  SARS-CoV-2: What is known and what there is to know-Focus on coagulation and lipids.

Authors:  Federico Carbone; Fabrizio Montecucco; Marcel Twickler
Journal:  Eur J Clin Invest       Date:  2020-06-25       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.